Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · IEX Real-Time Price · USD
2.390
-0.140 (-5.53%)
Jul 19, 2024, 4:00 PM EDT - Market closed
LIXT Employees
As of December 31, 2023, Lixte Biotechnology Holdings had 4 total employees, including 3 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,172,673
Market Cap
5.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Leafly Holdings | 131 |
| Biomerica | 62 |
| ENDRA Life Sciences | 21 |
| BioCardia | 20 |
| FSD Pharma | 17 |
| Aethlon Medical | 14 |
| TransCode Therapeutics | 10 |
| Synaptogenix | 5 |
LIXT News
- 5 weeks ago - LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial - GlobeNewsWire
- 5 weeks ago - LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial - GlobeNewsWire
- 6 weeks ago - Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System - GlobeNewsWire
- 7 weeks ago - LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer - GlobeNewsWire
- 2 months ago - LIXTE Biotechnology Holdings Provides Update on Recent Activities - GlobeNewsWire
- 2 months ago - LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” - GlobeNewsWire
- 4 months ago - LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments - GlobeNewsWire
- 5 months ago - Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research - GlobeNewsWire